167 related articles for article (PubMed ID: 19780253)
21. Impact of fluoroquinolone prophylaxis during neutropenia on bloodstream infection: Data from a surveillance program in 8755 patients receiving high-dose chemotherapy for haematologic malignancies between 2009 and 2014.
Kern WV; Weber S; Dettenkofer M; Kaier K; Bertz H; Behnke M; Weisser M; Götting T; Widmer AF; Theilacker C;
J Infect; 2018 Jul; 77(1):68-74. PubMed ID: 29883599
[TBL] [Abstract][Full Text] [Related]
22. Use of fluoroquinolones as prophylactic agents in patients with neutropenia.
Patrick CC
Pediatr Infect Dis J; 1997 Jan; 16(1):135-9; discussion 160-2. PubMed ID: 9002124
[TBL] [Abstract][Full Text] [Related]
23. Infections of febrile neutropenic patients in malignant hematological diseases.
Rókusz L; Liptay L
Mil Med; 2003 May; 168(5):355-9. PubMed ID: 12775168
[TBL] [Abstract][Full Text] [Related]
24. Epidemiology and prevention of bacterial infections in patients with hematologic malignancies.
Tessier J; Sifri CD
Infect Disord Drug Targets; 2011 Feb; 11(1):11-7. PubMed ID: 21303336
[TBL] [Abstract][Full Text] [Related]
25. Fluoroquinolones, antimicrobial resistance and neutropenic cancer patients.
Bow EJ
Curr Opin Infect Dis; 2011 Dec; 24(6):545-53. PubMed ID: 22001945
[TBL] [Abstract][Full Text] [Related]
26. Primary prophylaxis of bacterial infections and Pneumocystis jirovecii pneumonia in patients with hematological malignancies and solid tumors : guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO).
Neumann S; Krause SW; Maschmeyer G; Schiel X; von Lilienfeld-Toal M; ;
Ann Hematol; 2013 Apr; 92(4):433-42. PubMed ID: 23412562
[TBL] [Abstract][Full Text] [Related]
27. Utility of fosfomycin as antibacterial prophylaxis in patients with hematologic malignancies.
Zapolskaya T; Perreault S; McManus D; Topal JE
Support Care Cancer; 2018 Jun; 26(6):1979-1983. PubMed ID: 29322242
[TBL] [Abstract][Full Text] [Related]
28. [Evaluation of antibiotic prophylaxis in neutropenic patients with hematologic malignancies].
Delarive P; Baumgartner JD; Glauser MP; Cometta A
Schweiz Med Wochenschr; 2000 Dec; 130(48):1837-44. PubMed ID: 11132527
[TBL] [Abstract][Full Text] [Related]
29. Treatment with fluorated quinolones of febrile neutropenia in patients with hematologic malignancies.
Nenova IS; Goranov SE; Mateva NG; Ananoshtev NH
Folia Med (Plovdiv); 2003; 45(1):13-9. PubMed ID: 12943062
[TBL] [Abstract][Full Text] [Related]
30. [Antibiotic therapy in leukopenia].
Böhme A; Shah PM; Stille W; Hoelzer D
Praxis (Bern 1994); 1998 Sep; 87(36):1120-5. PubMed ID: 9782739
[TBL] [Abstract][Full Text] [Related]
31. Gram-negative organisms predominate in Hickman line-related infections in non-neutropenic patients with hematological malignancies.
Chee L; Brown M; Sasadeusz J; MacGregor L; Grigg AP
J Infect; 2008 Apr; 56(4):227-33. PubMed ID: 18342947
[TBL] [Abstract][Full Text] [Related]
32. Prevention of bacterial infection in neutropenic patients with hematologic malignancies. A randomized, multicenter trial comparing norfloxacin with ciprofloxacin. The GIMEMA Infection Program. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto.
Ann Intern Med; 1991 Jul; 115(1):7-12. PubMed ID: 2048868
[TBL] [Abstract][Full Text] [Related]
33. Antibiotic prophylaxis in neutropenic children with acute leukemia: Do the presently available data really support this practice?
Calitri C; Ruberto E; Castagnola E
Eur J Haematol; 2018 Dec; 101(6):721-727. PubMed ID: 30107054
[TBL] [Abstract][Full Text] [Related]
34. Prophylactic antibiotics for the prevention of neutropenic fever in patients undergoing autologous stem-cell transplantation: results of a single institution, randomized phase 2 trial.
Eleutherakis-Papaiakovou E; Kostis E; Migkou M; Christoulas D; Terpos E; Gavriatopoulou M; Roussou M; Bournakis E; Kastritis E; Efstathiou E; Dimopoulos MA; Papadimitriou CA
Am J Hematol; 2010 Nov; 85(11):863-7. PubMed ID: 20882526
[TBL] [Abstract][Full Text] [Related]
35. Clinical and microbiological effects of biapenem in febrile neutropenic patients with hematologic malignancies.
Isobe Y; Kanemitsu N; Yahata Y; Masuda A; Tsukune Y; Sugimoto K
Scand J Infect Dis; 2009; 41(3):237-9. PubMed ID: 19116887
[No Abstract] [Full Text] [Related]
36. Recent changes in bacterial epidemiology and the emergence of fluoroquinolone-resistant Escherichia coli among patients with haematological malignancies: results of a prospective study on 823 patients at a single institution.
Cattaneo C; Quaresmini G; Casari S; Capucci MA; Micheletti M; Borlenghi E; Signorini L; Re A; Carosi G; Rossi G
J Antimicrob Chemother; 2008 Mar; 61(3):721-8. PubMed ID: 18218645
[TBL] [Abstract][Full Text] [Related]
37. Fluoroquinolone prophylaxis in patients with neutropenia at high risk of serious infections: Exploring pros and cons.
Singh N; Thursky K; Maron G; Wolf J
Transpl Infect Dis; 2023 Nov; 25 Suppl 1():e14152. PubMed ID: 37746769
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of imipenem 1.5 g daily in febrile patients with short duration neutropenia after chemotherapy for non-leukemic hematologic malignancies and solid tumors: personal experience and review of the literature.
Jourdan E; Defez C; Topart D; Richard B; Bellabas H; Fabbro-Peray P; Jourdan J; Sotto A
Leuk Lymphoma; 2003 Apr; 44(4):619-26. PubMed ID: 12769338
[TBL] [Abstract][Full Text] [Related]
39. [Gram-negative bacteremia in neutropenic patients with hematologic disorders. Experiences with prophylactic use of fluoroquinolones].
Sinkó J; Cser V; Konkoly Thege M; Masszi T
Orv Hetil; 2011 Jul; 152(27):1063-7. PubMed ID: 21676672
[TBL] [Abstract][Full Text] [Related]
40. Extended follow-up of an antibiotic cycling program for the management of febrile neutropenia in a hematologic malignancy and hematopoietic cell transplantation unit.
Cumpston A; Craig M; Hamadani M; Abraham J; Hobbs GR; Sarwari AR
Transpl Infect Dis; 2013 Apr; 15(2):142-9. PubMed ID: 23279656
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
